Prediction of Anti‐Alzheimer's Activity of Flavonoids Targeting Acetylcholinesterase in silico

Das, Subrata; Laskar, Monjur A.; Sarker, Satyajit D.; Choudhury, Manabendra D.; Choudhury, Prakash Roy; Mitra, Abhijit̲; Jamil, Shajarahtunnur; Lathiff, Siti Mariam A.; Abdullah, Siti Awanis; Basar, Norazah; Nahar, Lutfun; Talukdar, Anupam D.

Prediction of Anti‐Alzheimer's Activity of Flavonoids Targeting Acetylcholinesterase in silico

2017

INTRODUCTION: Prenylated and pyrano‐flavonoids of the genus Artocarpus J. R. Forster & G. Forster are well known for their acetylcholinesterase (AChE) inhibitory, anti‐cholinergic, anti‐inflammatory, anti‐microbial, anti‐oxidant, anti‐proliferative and tyrosinase inhibitory activities. Some of these compounds have also been shown to be effective against Alzheimer's disease. OBJECTIVE: The aim of the in silico study was to establish protocols to predict the most effective flavonoid from prenylated and pyrano‐flavonoid classes for AChE inhibition linking to the potential treatment of Alzheimer's disease. METHODOLOGY: Three flavonoids isolated from Artocarpus anisophyllus Miq. were selected for the study. With these compounds, Lipinski filter, ADME/Tox screening, molecular docking and quantitative structure–activity relationship (QSAR) were performed in silico. In vitro activity was evaluated by bioactivity staining based on the Ellman's method. RESULTS: In the Lipinski filter and ADME/Tox screening, all test compounds produced positive results, but in the target fishing, only one flavonoid could successfully target AChE. Molecular docking was performed on this flavonoid, and this compound gained the score as ˗13.5762. From the QSAR analysis the IC₅₀ was found to be 1659.59 nM. Again, 100 derivatives were generated from the parent compound and docking was performed. The derivative compound 20 was the best scorer, i.e. ˗31.6392 and IC₅₀ was predicted as 6.025 nM. CONCLUSION: Results indicated that flavonoids could be efficient inhibitors of AChE and thus, could be useful in the management of Alzheimer's disease. Copyright © 2017 John Wiley & Sons, Ltd.

Afficher plus [+]